关注
Shi Hu
Shi Hu
在 smmu.edu.cn 的电子邮件经过验证
标题
引用次数
引用次数
年份
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
C Lei, K Qian, T Li, S Zhang, W Fu, M Ding, S Hu
Nature communications 11 (1), 1-5, 2020
4042020
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
W Fu, C Lei, S Liu, Y Cui, C Wang, K Qian, T Li, Y Shen, X Fan, F Lin, ...
Nature communications 10 (1), 1-12, 2019
3032019
Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view
S Hu, S Liang, H Guo, D Zhang, H Li, X Wang, W Yang, W Qian, S Hou, ...
Journal of Biological Chemistry 288 (38), 27059-27067, 2013
1782013
Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab
S Liang, J Dai, S Hou, L Su, D Zhang, H Guo, S Hu, H Wang, Z Rao, ...
Journal of Biological Chemistry 288 (19), 13799-13807, 2013
1232013
Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk
S Hu, W Fu, W Xu, Y Yang, M Cruz, SD Berezov, D Jorissen, H Takeda, ...
Cancer research 75 (1), 159-170, 2015
922015
Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 HeterodimerizationAn Anti-ErbB2 BsAb Circumvents Trastuzumab Resistance
B Li, Y Meng, L Zheng, X Zhang, Q Tong, W Tan, S Hu, H Li, Y Chen, ...
Cancer Research 73 (21), 6471-6483, 2013
722013
Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency
S Hu, W Fu, T Li, Q Yuan, F Wang, G Lv, Y Lv, X Fan, Y Shen, F Lin, ...
Science Translational Medicine 9 (380), eaag0339, 2017
682017
SOX10, a novel HMG-box-containing tumor suppressor, inhibits growth and metastasis of digestive cancers by suppressing the Wnt/β-catenin pathway
X Tong, L Li, X Li, L Heng, L Zhong, X Su, R Rong, S Hu, W Liu, B Jia, ...
Oncotarget 5 (21), 10571, 2014
652014
Molecular architecture of the ErbB2 extracellular domain homodimer
S Hu, Y Sun, Y Meng, X Wang, W Yang, W Fu, H Guo, W Qian, S Hou, B Li, ...
Oncotarget 6 (3), 1695, 2015
532015
EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell FrequencyTargeting CSC with Anti-EGFR/Notch Antibody
W Fu, C Lei, Y Yu, S Liu, T Li, F Lin, X Fan, Y Shen, M Ding, Y Tang, X Ye, ...
Clinical Cancer Research 25 (9), 2835-2847, 2019
342019
The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer
S Han, Y Meng, Q Tong, G Li, X Zhang, Y Chen, S Hu, L Zheng, W Tan, ...
MAbs 6 (2), 403-408, 2014
332014
Treatment of murine lupus with TIGIT-Ig
S Liu, L Sun, C Wang, Y Cui, Y Ling, T Li, F Lin, W Fu, M Ding, S Zhang, ...
Clinical Immunology 203, 72-80, 2019
302019
The roles of small extracellular vesicles in cancer and immune regulation and translational potential in cancer therapy
K Qian, W Fu, T Li, J Zhao, C Lei, S Hu
Journal of Experimental & Clinical Cancer Research 41 (1), 1-29, 2022
272022
Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer
S Hu, H Dai, T Li, Y Tang, W Fu, Q Yuan, F Wang, G Lv, Y Lv, X Fan, ...
Cancer Letters 382 (1), 32-43, 2016
272016
Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody
S Wang, C Chen, Y Meng, S Hu, L Zheng, J Song, D Zhang, B Li, Y Guo
Cancer letters 325 (2), 214-219, 2012
272012
CAR macrophages for SARS-CoV-2 immunotherapy
W Fu, C Lei, Z Ma, K Qian, T Li, J Zhao, S Hu
Frontiers in Immunology, 2907, 2021
262021
Treatment of murine lupus with PD-LIg
H Zhou, L Xiong, Y Wang, L Ding, S Hu, M Zhao, L Zhou
Clinical Immunology 162, 1-8, 2016
172016
Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody
X Yu, L Wang, Y Shen, C Wang, Y Zhang, Y Meng, Y Yang, B Liang, ...
Molecular Immunology 87, 300-307, 2017
162017
Targeting RyR2 with a phosphorylation site–specific nanobody reverses dysfunction of failing cardiomyocytes in rats
T Li, Y Shen, F Lin, W Fu, S Liu, C Wang, J Liang, X Fan, X Ye, Y Tang, ...
The FASEB Journal 33 (6), 7467-7478, 2019
92019
TIGIT-Fc as a potential therapeutic agent for fetomaternal tolerance
W Fu, R Cai, Z Ma, T Li, C Lei, J Zhao, S Hu
Frontiers in immunology 12, 649135, 2021
82021
系统目前无法执行此操作,请稍后再试。
文章 1–20